2-MAPB

A psychoactive drug of the phenethylamine and amphetamine classes

2-MAPB
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

2-MAPB (1-(2,3-dihydro-1H-inden-5-yl)-N-methylpropan-2-amine) is a psychoactive drug belonging to the phenethylamine and amphetamine classes. It is structurally related to other compounds such as MDMA and 2C-B.

Chemical structure and properties

2-MAPB is a synthetic compound with a chemical structure that includes a phenethylamine core with an additional methyl group attached to the nitrogen atom, classifying it as an amphetamine. The structure also features a 2,3-dihydro-1H-inden-5-yl group, which is a bicyclic structure that contributes to its unique pharmacological properties.

Pharmacology

2-MAPB acts as a serotonin and dopamine releasing agent, similar to other entactogens like MDMA. This action is responsible for its psychoactive effects, which include feelings of euphoria, increased sociability, and enhanced sensory perception. The exact mechanism of action involves the release of neurotransmitters from presynaptic neurons and inhibition of their reuptake.

Effects

The effects of 2-MAPB are similar to those of other entactogens and stimulants. Users report increased empathy, emotional openness, and a sense of well-being. The stimulant effects include increased energy and alertness. However, like other drugs in this class, it can also cause adverse effects such as anxiety, insomnia, and increased heart rate.

Legal status

The legal status of 2-MAPB varies by country. In some jurisdictions, it is classified as a controlled substance due to its structural similarity to other illegal drugs. In others, it may be unscheduled but subject to analogue laws that regulate substances with similar chemical structures and effects.

Safety and toxicity

There is limited information on the safety and toxicity of 2-MAPB. As with other research chemicals, the lack of comprehensive studies means that the long-term effects and potential risks are not well understood. Users are advised to exercise caution and be aware of the potential for adverse reactions.

Related compounds

• MDMA
• 2C-B
• MDA
• Amphetamine

See also

• Entactogen
• Psychedelic
• Stimulant

Related pages

• Phenethylamine
• Serotonin releasing agent
• Dopamine releasing agent